Skip to main content

Table 1 Summary of baseline patient characteristics

From: Association between histamine 2 receptor antagonists and sepsis outcomes in ICU patients: a retrospective analysis using the MIMI-IV database

 

No H2RA

(n = 17,683)

(57.8%)

H2RA

(n = 12,908)

(42.2%)

p value

Age, [median, years (IQR)]

69 (58–80)

66 (56–76)

< 0.01

Males

9842 (55.7%)

7829 (60.7%)

< 0.01

Race

  

< 0.01

 American Indian/Alaska Native

50 (0.3%)

19 (0.2%)

 

 Asian

508 (2.9%)

374 (2.9%)

 

 Black/African American

2062 (11.7%)

1078 (8.4%)

 

 Hispanic/Latino

640 (3.6%)

498 (3.9%)

 

 Other

754 (4.3%)

657 (5.1%)

 

 Unknown

1405 (7.9%)

1724 (13.4%)

 

 White

12,264 (69.4%)

8558 (66.3%)

 

Comorbid conditions

 AIDS

197 (1.1%)

82 (0.6%)

< 0.01

 Cerebrovascular disease

1942 (11.0%)

2256 (17.5%)

< 0.01

 Chronic pulmonary disease

5334 (30.2%)

3257 (25.2%)

< 0.01

 Congestive heart failure

6500 (36.8%)

3630 (28.1%)

< 0.01

 Dementia

1072 (6.1%)

373 (2.9%)

< 0.01

 Diabetes, chronic complications

2291 (13.0%)

1153 (8.9%)

< 0.01

 Diabetes no chronic complications

4629 (26.2%)

3042 (23.6%)

< 0.01

 Malignant cancer

2870 (16.2%)

1429 (11.1%)

< 0.01

 Metastatic solid tumor

1334 (7.5%)

610 (4.7%)

< 0.01

 Mild liver disease

3416 (19.3%)

1357 (10.5%)

< 0.01

 Myocardial infarction

3147 (17.8%)

2269 (17.6%)

0.62

 Paraplegia

653 (3.7%)

817 (6.3%)

< 0.01

 Peptic ulcer disease

850 (4.8%)

204 (1.9% )

< 0.01

 Peripheral vascular disease

2184 (12.4%)

1748 (13.5%)

< 0.01

 Renal disease

5474 (31.0%)

2533 (19.6%)

< 0.01

 Rheumatic disease

764 (4.3%)

405 (3.1%)

< 0.01

 Severe liver disease

2006 (11.3%)

520 (4.0%)

< 0.01

Charlson comorbidity index [median (IQR)]

6 (5–8)

5 (4–7)

< 0.01

APS III Score [median (IQR)]

51 (39–68)

48 (34–70)

< 0.01

SAPS II Score [median (IQR)]

38 (33–48)

38 (30–47)

< 0.01

OASIS Score [median (IQR)]

33 (27–39)

35 (29–41)

< 0.01

First Day SOFA Score

[median (IQR)]

5 (4–8)

6 (4–9)

< 0.01